Nordea Investment Management AB Makes New $2.36 Million Investment in TG Therapeutics, Inc. $TGTX

Nordea Investment Management AB acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 79,696 shares of the biopharmaceutical company’s stock, valued at approximately $2,356,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Royal Bank of Canada lifted its stake in TG Therapeutics by 16.4% during the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock worth $2,985,000 after purchasing an additional 10,660 shares during the last quarter. NewEdge Advisors LLC increased its stake in TG Therapeutics by 9.6% in the first quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 665 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after purchasing an additional 345,059 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in TG Therapeutics by 5.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after purchasing an additional 14,689 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of TG Therapeutics by 190.2% during the 2nd quarter. SG Americas Securities LLC now owns 9,289 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 6,088 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Price Performance

TGTX stock opened at $31.75 on Friday. The company has a current ratio of 4.10, a quick ratio of 3.29 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $5.07 billion, a P/E ratio of 11.46 and a beta of 1.87. The business has a 50 day simple moving average of $29.76 and a 200-day simple moving average of $31.49. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. The business had revenue of $192.57 million during the quarter, compared to analyst estimates of $192.15 million. During the same period in the previous year, the firm earned $0.15 earnings per share. The business’s revenue was up 78.0% compared to the same quarter last year. As a group, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. JPMorgan Chase & Co. cut their price target on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.00.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.